Combating Antimicrobial Resistance: A Fresh Perspective

TAXIS is researching new classes of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections. Our research efforts focus on the disruption of the foundation of bacterial cell wall architecture to address elemental drug resistance mechanisms.

ABOUT EFFLUX PUMP INHIBITION


TAXIS has identified numerous efflux pump inhibitor (EPI) candidate compounds that are synergistic with a wide range of currently marketed antibiotic agents, and thereby resurrect activity of these drugs,  providing low-cost access to life-saving medications.

ABOUT FtsZ MODULATION

The bacterial protein FtsZ plays an essential role in bacterial cell division and survival. TXA709, TAXIS’s most advanced drug candidate, modulates FtsZ by blocking post-mitotic septum formation within the bacterial cell.

ABOUT MREB MODULATION


MreB is a bacterial protein involved in maintaining the shape of rod-shaped bacteria such as Escherichia coli. Inhibition of MreB undermines bacterial cell shape integrity, polar protein localization and/or chromosome segregation.

taxis-home-1

Tackling the Antimicrobial Resistance Crisis


Overuse and misuse of antibiotic agents have contributed to the spread of resistant bacteria, posing a serious health risk that the World Health Organization (WHO) describes as a global health emergency. TAXIS is focused on developing new classes of antibiotic agents to treat life-threatening, multidrug-resistant bacterial infections.

Mission Statement


Our mission is to discover and develop unique therapeutic agents to address the global health crisis of antimicrobial resistance.